Devyser Diagnostics AB (STU:OL0)
€ 5.65 +0.080 (+1.44%) Market Cap: 95.43 Mil Enterprise Value: 93.06 Mil PE Ratio: 70.55 PB Ratio: 2.96 GF Score: 74/100

Q4 2025 Devyser Diagnostics AB Earnings Call Transcript

Feb 12, 2026 / 08:00 AM GMT
Release Date Price: €9.79 (+2.62%)

Key Points

Positve
  • Devyser Diagnostics AB (FRA:OL0) reported a record profitable quarter with $72 million in sales, marking a 20% growth compared to Q4 last year in local currencies.
  • The company achieved an EBIT of 18 million, delivering a 25% EBIT margin, a significant increase from last year's 3.7 million.
  • Devyser Diagnostics AB (FRA:OL0) has entered into an agreement to acquire Cybergen AB, which is expected to contribute positively to gross profit and margin.
  • The collaboration with Illumina positions Devyser Diagnostics AB (FRA:OL0) strongly in the market, leveraging Illumina's market leadership in DNA sequencing.
  • The company has maintained strong growth in North America, doubling revenues compared to 2024, and continues to expand its market share in Europe, particularly in Italy.
Negative
  • Gross margins came in at 79%, which was below expectations, and the company plans to work on improving margins in 2026.
  • Currency headwinds negatively impacted reported revenue growth, despite strong sales in local currencies.
  • The acquisition of Cybergen AB, while strategically beneficial, involves regulatory clearance and integration challenges.
  • The company's growth in the US remains relatively minor in absolute terms, with significant reliance on future regulatory approvals like Multi-X.
  • There is ongoing lumpiness in quarterly sales, particularly with distributor sales and partnerships like Thermo Fisher, which may affect revenue predictability.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DVYSR.ST - Devyser Diagnostics AB
Q4 2025 Devyser Diagnostics AB Earnings Call
Feb 12, 2026 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Devisor Q4 2025 earnings call. I'm Jan Wallstrom, CEO of Devisor, and I would like to thank you everyone for joining our call today.

Today's presenters on the call today, we have, in addition to myself, also our CFO Sabina Berlin and our CCO Ty Kipling.

I will start with a short summary of our quarterly result and then recap our recent activities that resulted in a record profitable quarter as well as a record sales quarter. I will give you an update on the recent product launches and present some additional highlights from the quarter before handing over to Savina for a more detailed review of our financial results in Q4 2025 and then to Ties for an update on our recent commercial
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot